ICOSLG Human
Sf9, Baculovirus cells.
Inducible T-Cell Costimulator Ligand, B7-Related Protein 1, B7 Homolog 2, B7-Like Protein Gl50, B7 Homologue 2, B7RP-1, ICOSL, B7-H2, B7RP1, B7H2, Transmembrane Protein B7-H2 ICOS Ligand, Inducible T-Cell Co-Stimulator Ligand, CD275 Antigen, ICOS Ligand, KIAA0653, ICOS-L, CD275, LICOS, GL50, ICOS ligand, B7 homolog 2, B7-H2, B7-like protein Gl50, B7-related protein 1, B7RP-1.
Greater than 90.0% as determined by SDS-PAGE.
Description
ICOSLG produced in Sf9 Baculovirus cells is a single, glycosylated polypeptide chain containing 480 amino acids (19-256a.a.) and having a molecular mass of 53.7kDa (Molecular size on SDS-PAGE will appear at approximately 50-70kDa).
ICOSLG is expressed with a 239 amino acid hIgG-His-tag at C-Terminus and purified by proprietary chromatographic techniques.
Product Specs
Inducible T-Cell Costimulator Ligand, also known as ICOSLG, belongs to the B7 family of co-stimulatory molecules, which includes B7-1 and B7-2. This transmembrane glycoprotein possesses extracellular IgV and IgC domains and binds to ICOS on activated T cells, playing a crucial role in their proliferative response through ICOSLG-dependent signaling.
Produced in Sf9 Baculovirus cells, our ICOSLG is a single, glycosylated polypeptide chain comprising 480 amino acids (19-256a.a.). It has a molecular mass of 53.7kDa, although it may appear between 50-70kDa on SDS-PAGE due to glycosylation. The protein is expressed with a C-terminal 239 amino acid hIgG-His-tag and purified using proprietary chromatographic techniques.
The ICOSLG protein solution is provided at a concentration of 1mg/ml in Phosphate Buffered Saline (pH 7.4) with 10% glycerol.
The purity of our ICOSLG is determined to be greater than 90.0% by SDS-PAGE analysis.
Inducible T-Cell Costimulator Ligand, B7-Related Protein 1, B7 Homolog 2, B7-Like Protein Gl50, B7 Homologue 2, B7RP-1, ICOSL, B7-H2, B7RP1, B7H2, Transmembrane Protein B7-H2 ICOS Ligand, Inducible T-Cell Co-Stimulator Ligand, CD275 Antigen, ICOS Ligand, KIAA0653, ICOS-L, CD275, LICOS, GL50, ICOS ligand, B7 homolog 2, B7-H2, B7-like protein Gl50, B7-related protein 1, B7RP-1.
Sf9, Baculovirus cells.
ADPDTQEKEV RAMVGSDVEL SCACPEGSRF DLNDVYVYWQ TSESKTVVTY HIPQNSSLEN VDSRYRNRAL MSPAGMLRGD FSLRLFNVTP QDEQKFHCLV LSQSLGFQEV LSVEVTLHVA ANFSVPVVSA PHSPSQDELT FTCTSINGYP RPNVYWINKT DNSLLDQALQ NDTVFLNMRG LYDVVSVLRI ARTPSVNIGC CIENVLLQQN LTVGSQTGND IGERDKITEN PVSTGEKNAA TLEPKSCDKT HTCPPCPAPE LLGGPSVFLF PPKPKDTLMI SRTPEVTCVV VDVSHEDPEV KFNWYVDGVE VHNAKTKPRE EQYNSTYRVV SVLTVLHQDW LNGKEYKCKV SNKALPAPIE KTISKAKGQP REPQVYTLPP SRDELTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT TPPVLDSDGS FFLYSKLTVD KSRWQQGNVF SCSVMHEALH NHYTQKSLSL SPGKHHHHHH.
Product Science Overview
Inducible T-cell costimulator ligand (ICOSL), also known as CD275, is a transmembrane protein that plays a crucial role in the immune system. It belongs to the B7 family of proteins and is primarily expressed on antigen-presenting cells (APCs) such as B cells, dendritic cells, and monocytes . The interaction between ICOSL and its receptor, inducible T-cell costimulator (ICOS), is essential for the activation and regulation of T cells .
ICOSL is a member of the B7 family and shares structural similarities with other family members, such as CD80 and CD86 . It is expressed on various cell types, including endothelial cells, fibroblasts, epithelial cells, and several types of tumor cells . The expression of ICOSL is upregulated in response to inflammatory signals, which enhances its interaction with ICOS on activated T cells .
The primary function of ICOSL is to bind to ICOS, a costimulatory receptor expressed on activated T cells . This interaction provides a crucial second signal for T-cell activation, proliferation, and differentiation. ICOSL-ICOS signaling is essential for the development and function of follicular helper T cells (Tfh), which play a vital role in the formation of germinal centers and the production of high-affinity antibodies .
In addition to its role in normal immune responses, ICOSL-ICOS signaling has been implicated in various pathological conditions, including autoimmune diseases and cancer . For instance, the interaction between ICOSL and ICOS can promote the expansion of regulatory T cells (Tregs), which suppress immune responses and contribute to tumor immune evasion .
Given its critical role in immune regulation, ICOSL has emerged as a potential therapeutic target for various diseases. Recombinant ICOSL (human recombinant) has been developed to modulate ICOSL-ICOS signaling in therapeutic applications . For example, activating ICOSL-ICOS signaling using recombinant ICOSL or agonist monoclonal antibodies (mAbs) has shown promise in enhancing antitumor immune responses .
In cancer therapy, combining ICOSL-ICOS activation with other immunotherapies, such as programmed cell death protein 1 (PD-1) blockade, has demonstrated synergistic effects in preclinical models . This combination approach aims to enhance the activation of antitumor T cells and improve the overall efficacy of cancer immunotherapy .
